Carmichael Hill & Associates, Inc. Verrica Pharmaceuticals Inc. Transaction History
Carmichael Hill & Associates, Inc.
- $279 Million
- Q3 2024
A detailed history of Carmichael Hill & Associates, Inc. transactions in Verrica Pharmaceuticals Inc. stock. As of the latest transaction made, Carmichael Hill & Associates, Inc. holds 21 shares of VRCA stock, worth $166. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21
Previous 21
-0.0%
Holding current value
$166
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VRCA
# of Institutions
71Shares Held
17.4MCall Options Held
6.1KPut Options Held
6.3K-
Perceptive Advisors LLC New York, NY7.1MShares$56.4 Million1.5% of portfolio
-
Avoro Capital Advisors LLC New York, NY4MShares$31.8 Million0.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.27MShares$10.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.13MShares$8.98 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA463KShares$3.68 Million0.0% of portfolio
About Verrica Pharmaceuticals Inc.
- Ticker VRCA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,094,100
- Market Cap $327M
- Description
- Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...